Is Medicamen Biotec overvalued or undervalued?

As of 14 November 2025, Medicamen Biotec's valuation grade has moved from very expensive to expensive, indicating a shift in its perceived value. The company is currently considered overvalued. Key ratios include a PE ratio of 58.40, an EV to EBITDA of 38.85, and a PEG ratio of 2.88, all of which suggest that the stock is trading at a premium compared to its earnings growth potential.
In comparison to its peers, Medicamen Biotec's PE ratio significantly exceeds that of Sun Pharma (36.49) and is higher than Torrent Pharma (60.06), both of which are also classified as expensive. Notably, Cipla stands out as attractive with a PE ratio of 22.72, indicating a more favorable valuation in the sector. Additionally, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -19.84% compared to the Sensex's 8.22%, further reinforcing the notion that Medicamen Biotec is overvalued in the current market environment.